Free Trial
→ The Iran War Isn’t Chaos. It’s Strategy. (From Behind the Markets) (Ad)tc pixel
NASDAQ:PSNL

Personalis Q3 2026 Earnings Date & Estimates

Personalis logo
$15.65 -0.28 (-1.76%)
Closing price 04:00 PM Eastern
Extended Trading
$15.47 -0.18 (-1.12%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Personalis is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, after market closes. The conference call is scheduled for 5:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
5:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Personalis in Q3 2026

Personalis is expected to post earnings of -$0.2625 per share on revenue of $21.54 million. In the same quarter a year earlier Personalis reported -$0.24 per share on revenue of $14.50 million. Personalis last reported on August 4, 2026, posting -$0.30 per share and missing the -$0.2633 consensus estimate. Personalis has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.2625
Expected Revenue
$21.54 million
Prior-Year EPS
-$0.24
Prior-Year Revenue
$14.50 million
Expected Revenue Growth
+48.6%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.30 (Missed by -$0.0367)
Last Quarter Revenue
$22.36 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Personalis Q3 2026 Earnings FAQ

Personalis (NASDAQ:PSNL) is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Personalis' Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 5:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Personalis to post earnings of -$0.2625 per share for Q3 2026.

The consensus revenue estimate for Personalis is $21.54 million for Q3 2026.

Personalis Earnings Headlines

Personalis-Tempus merger clears key regulatory milestone
October 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/personalis-tempus-merger-clears-key-regulatory-milestone?utm_source=marketbeat.com&utm_medium=referral
Personalis downgraded at BTIG on likely Tempus takeover
October 6, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/personalis-downgraded-at-btig-on-likely-tempus-takeover/ar-AA2dGLvm
Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.tc pixel
October 16 at 1:00 AM  |  Weiss Ratings (Ad)
BTIG Downgrades Personalis to Neutral From Buy
October 6, 2026  |  marketscreener.comM
Personalis: The Wrong Side Of The Merger
September 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4950916-personalis-the-wrong-side-of-the-merger
《美股主題週報》精準醫療檢測—TEM、ILMN、PSNL
September 29, 2026  |  tw.stock.yahoo.comhttps://tw.stock.yahoo.com/news/%E7%BE%8E%E8%82%A1%E4%B8%BB%E9%A1%8C%E9%80%B1%E5%A0%B1-%E7%B2%BE%E6%BA%96%E9%86%AB%E7%99%82%E6%AA%A2%E6%B8%AC-tem-ilmn-psnl-083500961.html
See More Personalis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Personalis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Personalis and other key companies, straight to your email.

About Personalis

Personalis (NASDAQ:PSNL) is a genomics company focused on precision oncology and advanced genetic testing. The company develops and commercializes molecular diagnostic products designed to help identify cancer-related genomic changes, monitor disease progression and support treatment decisions.

Its product portfolio includes the NeXT platform, which is used to analyze tumor and blood samples. Offerings have included tissue-based profiling, liquid biopsy testing and personalized minimal residual disease monitoring intended to detect small amounts of cancer remaining after treatment or to identify signs of recurrence. Personalis also provides genomic analysis and testing services for biopharmaceutical companies developing cancer therapies and conducting clinical trials.

Founded in 2011 and headquartered in Fremont, California, Personalis initially provided large-scale genomic sequencing and analysis services before focusing more heavily on oncology. The company serves pharmaceutical and biotechnology customers, healthcare organizations and research partners, with testing and genomic services available through collaborations and clinical programs in the United States and other markets.

View Personalis Profile
Earnings Tools